FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161808511> ?p ?o ?g. }

• W2161808511 endingPage "1396" @default.
• W2161808511 startingPage "1389" @default.
• W2161808511 abstract "ObjectiveTo examine whether attention-deficit/hyperactivity disorder (ADHD) stimulant medication modified the linear growth response to growth hormone (GH) treatment in children enrolled in the American Norditropin Studies: Web-Enabled Research Program.Study designShort, GH treatment-naive children with or without GH deficiency (GHD) received GH therapy. A subset also received ADHD stimulant medication (n = 1190), and others did not (n = 7230). Linear mixed models (adjusted means) examined height SDS (HSDS) and body mass index (BMI) SDS from baseline through year 4. Analyses were repeated with ADHD groups matched for baseline age, height, weight, BMI, and sex. Groups with and without GHD were compared between ADHD groups.ResultsAdjusted change in HSDS for the group receiving ADHD stimulant medication was slightly lower than that for patients not receiving stimulant medication at years 1 to 4 (P < .05). However, adjusted change in HSDS was similar between children receiving and not receiving ADHD stimulant medication when matched for baseline measurements. At year 4, 86.7% of patients receiving ADHD stimulant medication, 86.8% of total patients not receiving ADHD stimulant medication, and 84.6% of matched group patients not receiving ADHD stimulant medication achieved HSDS >−2. Year 4 adjusted change in BMI SDS was greater in the patients receiving ADHD stimulant medication compared with both groups not receiving ADHD stimulant medication (P < .05). Patients with GHD showed comparable differences in adjusted change in BMI SDS among the ADHD groups at year 4, whereas patients without GHD showed no significant differences.ConclusionsADHD medication did not affect the linear growth response of children treated with GH when those receiving or not receiving ADHD stimulant medication were matched for baseline measurements. Underlying reasons for the observed greater increase in BMI in patients with GHD concomitantly treated with ADHD medication remain to be elucidated.Trial registrationClinicalTrials.gov: NCT01009905. To examine whether attention-deficit/hyperactivity disorder (ADHD) stimulant medication modified the linear growth response to growth hormone (GH) treatment in children enrolled in the American Norditropin Studies: Web-Enabled Research Program. Short, GH treatment-naive children with or without GH deficiency (GHD) received GH therapy. A subset also received ADHD stimulant medication (n = 1190), and others did not (n = 7230). Linear mixed models (adjusted means) examined height SDS (HSDS) and body mass index (BMI) SDS from baseline through year 4. Analyses were repeated with ADHD groups matched for baseline age, height, weight, BMI, and sex. Groups with and without GHD were compared between ADHD groups. Adjusted change in HSDS for the group receiving ADHD stimulant medication was slightly lower than that for patients not receiving stimulant medication at years 1 to 4 (P < .05). However, adjusted change in HSDS was similar between children receiving and not receiving ADHD stimulant medication when matched for baseline measurements. At year 4, 86.7% of patients receiving ADHD stimulant medication, 86.8% of total patients not receiving ADHD stimulant medication, and 84.6% of matched group patients not receiving ADHD stimulant medication achieved HSDS >−2. Year 4 adjusted change in BMI SDS was greater in the patients receiving ADHD stimulant medication compared with both groups not receiving ADHD stimulant medication (P < .05). Patients with GHD showed comparable differences in adjusted change in BMI SDS among the ADHD groups at year 4, whereas patients without GHD showed no significant differences. ADHD medication did not affect the linear growth response of children treated with GH when those receiving or not receiving ADHD stimulant medication were matched for baseline measurements. Underlying reasons for the observed greater increase in BMI in patients with GHD concomitantly treated with ADHD medication remain to be elucidated." @default.
• W2161808511 created "2016-06-24" @default.
• W2161808511 creator A5005138292 @default.
• W2161808511 creator A5056652115 @default.
• W2161808511 creator A5063997836 @default.
• W2161808511 creator A5064058928 @default.
• W2161808511 date "2015-12-01" @default.
• W2161808511 modified "2023-09-26" @default.
• W2161808511 title "Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study" @default.
• W2161808511 cites W1840897701 @default.
• W2161808511 cites W1979632837 @default.
• W2161808511 cites W1979868813 @default.
• W2161808511 cites W1982914778 @default.
• W2161808511 cites W2012784662 @default.
• W2161808511 cites W2035815084 @default.
• W2161808511 cites W2042215134 @default.
• W2161808511 cites W2045788872 @default.
• W2161808511 cites W2077454035 @default.
• W2161808511 cites W2106031705 @default.
• W2161808511 cites W2128962458 @default.
• W2161808511 cites W2154092650 @default.
• W2161808511 cites W2154426538 @default.
• W2161808511 cites W2168336778 @default.
• W2161808511 cites W2170451465 @default.
• W2161808511 cites W2172081237 @default.
• W2161808511 cites W2325252049 @default.
• W2161808511 doi "https://doi.org/10.1016/j.jpeds.2015.08.036" @default.
• W2161808511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26394822" @default.
• W2161808511 hasPublicationYear "2015" @default.
• W2161808511 type Work @default.
• W2161808511 sameAs 2161808511 @default.
• W2161808511 citedByCount "7" @default.
• W2161808511 countsByYear W21618085112017 @default.
• W2161808511 countsByYear W21618085112019 @default.
• W2161808511 countsByYear W21618085112020 @default.
• W2161808511 countsByYear W21618085112021 @default.
• W2161808511 countsByYear W21618085112022 @default.
• W2161808511 countsByYear W21618085112023 @default.
• W2161808511 crossrefType "journal-article" @default.
• W2161808511 hasAuthorship W2161808511A5005138292 @default.
• W2161808511 hasAuthorship W2161808511A5056652115 @default.
• W2161808511 hasAuthorship W2161808511A5063997836 @default.
• W2161808511 hasAuthorship W2161808511A5064058928 @default.
• W2161808511 hasBestOaLocation W21618085111 @default.
• W2161808511 hasConcept C118552586 @default.
• W2161808511 hasConcept C126322002 @default.
• W2161808511 hasConcept C187212893 @default.
• W2161808511 hasConcept C2780221984 @default.
• W2161808511 hasConcept C2780557958 @default.
• W2161808511 hasConcept C2780783007 @default.
• W2161808511 hasConcept C71924100 @default.
• W2161808511 hasConceptScore W2161808511C118552586 @default.
• W2161808511 hasConceptScore W2161808511C126322002 @default.
• W2161808511 hasConceptScore W2161808511C187212893 @default.
• W2161808511 hasConceptScore W2161808511C2780221984 @default.
• W2161808511 hasConceptScore W2161808511C2780557958 @default.
• W2161808511 hasConceptScore W2161808511C2780783007 @default.
• W2161808511 hasConceptScore W2161808511C71924100 @default.
• W2161808511 hasIssue "6" @default.
• W2161808511 hasLocation W21618085111 @default.
• W2161808511 hasLocation W21618085112 @default.
• W2161808511 hasOpenAccess W2161808511 @default.
• W2161808511 hasPrimaryLocation W21618085111 @default.
• W2161808511 hasRelatedWork W2032761690 @default.
• W2161808511 hasRelatedWork W2111459430 @default.
• W2161808511 hasRelatedWork W2415478367 @default.
• W2161808511 hasRelatedWork W2809610821 @default.
• W2161808511 hasRelatedWork W3027597886 @default.
• W2161808511 hasRelatedWork W3040281118 @default.
• W2161808511 hasRelatedWork W4280592170 @default.
• W2161808511 hasRelatedWork W4310493648 @default.
• W2161808511 hasRelatedWork W4322724587 @default.
• W2161808511 hasRelatedWork W2126205803 @default.
• W2161808511 hasVolume "167" @default.
• W2161808511 isParatext "false" @default.
• W2161808511 isRetracted "false" @default.
• W2161808511 magId "2161808511" @default.
• W2161808511 workType "article" @default.